Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
about
Contrasting Adult and Infant Immune Responses to HIV Infection and VaccinationPost-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virusA New Scientific Paradigm may be Needed to Finally Develop an HIV VaccineHIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.Progress in HIV-1 vaccine development.Recent developments in clinical trial designs for HIV vaccine researchWill HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users' anticipated risk compensationHumoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin UsersGeneration and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern AfricaSurvivors Remorse: antibody-mediated protection against HIV-1.HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentCurrent views on the potential for development of a HIV vaccine.Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand.Lessons learned from human HIV vaccine trials.HIV-1 vaccines: challenges and new perspectivesNovel directions in HIV-1 vaccines revealed from clinical trialsAntibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenA novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infectionComparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination RegimensA Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine RegimensAdvancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesHIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesFCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.Fcgbp - A Potential Viral Trap in RV144Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding.Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users.Immunology. Immune activation with HIV vaccinesHuman immunodeficiency virus vaccinesA critical question for HIV vaccine development: which antibodies to induce?An HIV Vaccine for South-East Asia-Opportunities and Challenges.Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward.Can immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges?Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques.
P2860
Q26776518-936A98C5-744D-48D4-AAFD-C9829EEA993CQ26797870-E946E244-280B-4B8D-A60F-1C9C52A91889Q26830360-6EBD92B8-1E6F-4C3C-9FE0-B287E1C5AA45Q27687375-F48951CB-3784-4011-8A70-A428018C7A0BQ27693849-42352630-AB97-465E-AF21-6CABC4BED5F8Q28083514-9A5444F4-6461-450B-BAD4-5F1D48F33088Q28540319-D5FE50AE-B12E-4CE9-AC79-5CCFA9196FB3Q28552355-98A8792E-E8C9-48EA-AEF0-24F4F270282BQ28552786-155E8A91-DBAB-48C9-BFA0-BA82F3A3AB93Q30238730-E7B985BE-2B61-4F15-864B-906DAEDE9B9AQ30355260-AB46BFD5-F871-43A3-8401-EECC5CF56B09Q30397595-6D6B44DA-34EF-4998-B75F-C1D709000C2DQ33423120-1D60E88E-B309-4291-99A1-A6C0CED9B8BDQ33557844-9C035157-823F-4F95-A111-2B6BDFC7DF05Q33577972-6E450A55-A73B-4B87-B550-4BDFA6507964Q33645528-60D35BFC-2DC5-4CBA-9E2F-4C8138A2E699Q33663463-8A62763F-7708-499C-933C-1E6A3A41405DQ33683355-F10AF3E9-88D3-41AD-8F19-900809ECFA44Q33712296-CF87C844-B52A-44FE-B963-8266BAC3DB2BQ33720317-9FB69824-7F88-452C-8E01-FF85C2D8176FQ33742529-16C7D717-FB7B-44FD-9676-BE3A8AD1A200Q33804531-E1901BE1-1498-49E8-8E76-CD377CD8CB47Q33813145-C8757EB0-D1D9-4337-9863-BBB9C921D720Q33869332-8F7377AB-60AA-4197-BC47-90C481175F14Q33977866-9460BB83-8A5A-4AD1-A221-32EADCA3DF3FQ34057711-59335D48-5358-4DE4-93DC-C0EC67EC600DQ34117524-00728FC7-A06D-49D3-80FD-1B369C6893E9Q34201287-8DDA6395-066D-4B8D-8B41-D6676D37BD47Q34298408-041FE69B-C77D-4606-A211-1C05B9319522Q34303849-68BA7F1B-E0FE-4C17-A1A2-AFC37FC47BCBQ34399508-1FFAF716-CA83-49AF-AA76-A19002C59572Q34480617-AB7C6420-EE35-4D4A-A140-6ECB1B279149Q34802271-3894C327-4A53-47F4-8E3E-64B2D2D51550Q35551760-7BF81E52-CA29-4866-A4C1-1BA0C05EBAD9Q35674731-D88FE93A-35D3-4D2E-9A6A-5E836384612DQ35783015-F7A8BD45-64AD-4D0B-AEC0-C0E0123AB316Q35826681-3DAE8F58-2CA7-44D7-9C6B-D63B170320A3Q35857623-9DAFA775-8DBF-4F6D-B7E4-1130F249A2D1Q35923859-1C9986D2-C15A-45FC-8DC1-4210CA62F2DDQ35989484-EE61025F-4164-4541-9415-57617E80424E
P2860
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Risk behaviour and time as cov ...... phase 3 efficacy trial RV 144.
@ast
Risk behaviour and time as cov ...... phase 3 efficacy trial RV 144.
@en
type
label
Risk behaviour and time as cov ...... phase 3 efficacy trial RV 144.
@ast
Risk behaviour and time as cov ...... phase 3 efficacy trial RV 144.
@en
prefLabel
Risk behaviour and time as cov ...... phase 3 efficacy trial RV 144.
@ast
Risk behaviour and time as cov ...... phase 3 efficacy trial RV 144.
@en
P2093
P2860
P50
P921
P1476
Risk behaviour and time as cov ...... phase 3 efficacy trial RV 144
@en
P2093
Chirasak Khamboonruang
Don Stablein
Donald Francis
Elizabeth Adams
Jim Tartaglia
Joseph Chiu
Michael Benenson
Patricia Morgan
Peter Gilbert
Prasert Thongcharoen
P2860
P304
P356
10.1016/S1473-3099(12)70088-9
P577
2012-05-30T00:00:00Z